Clinical Trial

Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)

Study acronym: OPTIMUS-CABG
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the effect of prasugrel plus low-dose aspirin versus high dose aspirin alone (300mg) and versus low dose aspirin alone (75 mg) in patients with chronic coronary disease undergoing coronary artery bypass grafting.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-09-25; most recent amendment 2026-07-12.
Status change: Not Yet Recruiting → Recruiting 2025-11-28
Trial Details
NCT Number NCT07195149
Lead Sponsor Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.
Collaborators: Medical Research Agency, Poland
Conditions Chronic Coronary Syndrome, Stable Coronary Artery Disease CAD
Enrollment 1,703 participants
Start Date 2025-11-25
Primary Completion 2030-04-30 (estimated)
Study Completion 2030-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-14